EUZd Stock Overview
Manufactures and sells isotope technology components worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Eckert & Ziegler SE Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €43.85 |
| 52 Week High | €47.30 |
| 52 Week Low | €36.44 |
| Beta | 1.33 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -59.77% |
| 5 Year Change | -2.56% |
| Change since IPO | 764.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| EUZd | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | 0% | 7.7% | -0.4% |
| 1Y | n/a | -2.1% | 5.6% |
Return vs Industry: Insufficient data to determine how EUZd performed against the UK Medical Equipment industry.
Return vs Market: Insufficient data to determine how EUZd performed against the UK Market.
Price Volatility
| EUZd volatility | |
|---|---|
| EUZd Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: EUZd's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: Insufficient data to determine EUZd's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,085 | Harald Hasselmann | www.ezag.com |
Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; ophthalmological products; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceuticals, laboratory equipment, radiosynthesis equipment, quality-control equipment, consumables, therapeutic products and plant engineering, and other services.
Eckert & Ziegler SE Fundamentals Summary
| EUZd fundamental statistics | |
|---|---|
| Market cap | €802.13m |
| Earnings (TTM) | €37.68m |
| Revenue (TTM) | €277.71m |
21.3x
P/E Ratio2.9x
P/S RatioIs EUZd overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EUZd income statement (TTM) | |
|---|---|
| Revenue | €277.71m |
| Cost of Revenue | €144.30m |
| Gross Profit | €133.42m |
| Other Expenses | €95.74m |
| Earnings | €37.68m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Mar 27, 2025
| Earnings per share (EPS) | 1.81 |
| Gross Margin | 48.04% |
| Net Profit Margin | 13.57% |
| Debt/Equity Ratio | 8.6% |
How did EUZd perform over the long term?
See historical performance and comparison